Since my article from October, "What To Expect From Gilead in Q3 2025", Gilead Sciences' stock ( GILD) reached an all-time ...

Rich countries are opening up societies and vaccinating young people who are not at great risk from Covid-19, while the poorest countries cruelly lack doses, the World Health Organization said on ...

President Donald Trump, left, and Fed Chair Jerome Powell have clashed before, but Powell's reaction is new. Heading into 2026, Bespoke Investment Group asked clients to choose what they thought were ...

Stocks declined Monday as investors fretted over the Trump administration’s threat of criminal charges against the Federal ...

The aid consignment includes essential items such as blankets, tents, buckets, basins and tubular elastic bandages. These ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.16%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.17%, ...

Investors shook off news of a Justice Department probe into Federal Reserve Chair Jerome Powell on Monday, with the S&P 500 ...

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...

A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...

Dax Shepard agrees with fans who think he looks like he’s had plastic surgery. Shepard, 51, said during the Monday, January 12, episode of his “Armchair Expert” podcast that he realized how “different ...

Phase III trial involved 594 patients across 20 countries Ceralasertib-Imfinzi combo showed no new safety concerns AstraZeneca shares fall 1% after trial results Dec 22 (Reuters) - AstraZeneca (AZN.L) ...